{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:14:42Z","timestamp":1761743682699},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[1992,4,1]],"date-time":"1992-04-01T00:00:00Z","timestamp":702086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":10143,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1992,4]]},"DOI":"10.1093\/annonc\/3.suppl_2.s115","type":"journal-article","created":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T21:52:48Z","timestamp":1353361968000},"page":"S115-S118","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S2","title":["Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO)"],"prefix":"10.1016","volume":"3","author":[{"given":"S.","family":"Frustaci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Foladore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"De Pascale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Freschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Lo","family":"Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Errante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Monfardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1093\/annonc\/3.suppl_2.S115_bb0100","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/jnci\/80.8.556","article-title":"Ifosfamide","volume":"80","author":"Zalupski","year":"1988","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1093\/annonc\/3.suppl_2.S115_bb0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0305-7372(87)90041-7","article-title":"MESNA \u2013 a short review","volume":"14","author":"Shaw","year":"1987","journal-title":"Cancer Treatment Review"},{"key":"10.1093\/annonc\/3.suppl_2.S115_bb0110","first-page":"1377","article-title":"Toxicology, pharmacology, and interaction of sodium 2-mercaptoethane sulfonate (mesna)","volume":"17","author":"Pohl","year":"1981","journal-title":"Curr Chemother"},{"key":"10.1093\/annonc\/3.suppl_2.S115_bb0115","first-page":"85","article-title":"Etudes biochimiques, meta-boliques et pharmacologiques d\u2019un mucolytique: le Mistabron","volume":"22","author":"Gobert","year":"1971","journal-title":"Acta Anaesth Belg"},{"key":"10.1093\/annonc\/3.suppl_2.S115_bb0120","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0277-5379(85)90079-3","article-title":"Excretion of sodium 2-mer-captoethanesulphonate (mesna) in the urine of volunteers","volume":"21","author":"Jones","year":"1985","journal-title":"Eur J Clin Oncol"},{"key":"10.1093\/annonc\/3.suppl_2.S115_bb0125","first-page":"1597","article-title":"Oral mesna bioavailability","volume":"34","author":"Burkert","year":"1984","journal-title":"Arzneimittel Forschung"},{"key":"10.1093\/annonc\/3.suppl_2.S115_bb0130","series-title":"XXV National Congress of the Italian Society of Pharmacology, Taormina, 14\u201318.10.1990","article-title":"Valutazione comparativa di propriet\u00e1 farmacotossicologiche e farmacocinetiche di due sali di mercaptoetanosulfonato: sale di sodio (mesna) e di arginina (argimesna)","author":"Miglioli","year":"1990"},{"key":"10.1093\/annonc\/3.suppl_2.S115_bb0135","series-title":"ABPI data sheet compendium-uromitexan","first-page":"1500","year":"1986"},{"issue":"Suppl.A","key":"10.1093\/annonc\/3.suppl_2.S115_bb0140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0305-7372(83)80026-7","article-title":"Clinical overview of mesna","volume":"10","author":"Burkert","year":"1983","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1093\/annonc\/3.suppl_2.S115_bb0145","first-page":"473","article-title":"Arginine 2-mercaptoethane sulfonate and sodium 2-mercaptoethane sulfonate: a comparative study of their effects upon tumour cells","volume":"XIV","author":"Magnolfi Zipoli","year":"1988","journal-title":"Drugs Exptl. Clin Res."},{"key":"10.1093\/annonc\/3.suppl_2.S115_bb0150","first-page":"1155","article-title":"Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention","volume":"17","author":"Brock","year":"1981","journal-title":"II. Comparative study on the uroprotective efficacy of thiols and other sulphur compounds. Eur J Cancer Clin Oncol"},{"issue":"A","key":"10.1093\/annonc\/3.suppl_2.S115_bb0155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0305-7372(83)80007-3","article-title":"Mesna versus forced diuresis to prevent cyclophosphamide-induced haemorrhagic cystitis in marrow transplantation patients (preliminary data)","volume":"10","author":"Hows","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/3.suppl_2.S115_bb0160","unstructured":"Anon. In New horizons in cancer chemotherapy. Boeringer Ingelheim Hospital Division, Ellesfield Avenue, Bracknell, Berks, U.K."},{"key":"10.1093\/annonc\/3.suppl_2.S115_bb0165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/oxfordjournals.annonc.a057775","article-title":"Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients","volume":"1","author":"Cerny","year":"1990","journal-title":"Annals of Oncology"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419662344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419662344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/3\/suppl_2\/S115\/330546\/3-suppl_2-S115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T02:54:46Z","timestamp":1582253686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419662344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,4]]},"references-count":14,"alternative-id":["S0923753419662344"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/3.suppl_2.s115","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1992,4]]}}}